Iterum Therapeutics Plc [ITRM] stock is trading at $1.49, up 17.79%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ITRM shares have gain 16.41% over the last week, with a monthly amount glided 4.93%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, Iterum Therapeutics Provides Business Update. In a post published today on Yahoo Finance, Resubmission of NDA is On Track for First Half of Q2 24.
From an analyst’s perspective:
Iterum Therapeutics Plc [NASDAQ: ITRM] stock has seen the most recent analyst activity on May 28, 2021, when Gabelli & Co upgraded its rating to a Hold. Previously, H.C. Wainwright upgraded its rating to Buy on March 15, 2021, and kept the price target unchanged to $2.50. On June 02, 2020, downgrade downgraded it’s rating to Sector Perform and revised its price target to $2 on the stock. Gabelli & Co downgraded its rating to a Sell. SVB Leerink downgraded its rating to a Mkt Perform. H.C. Wainwright started tracking with a Buy rating for this stock on June 21, 2019, and assigned it a price target of $17.
Iterum Therapeutics Plc [ITRM] stock has fluctuated between $0.62 and $2.50 over the past year. Iterum Therapeutics Plc [NASDAQ: ITRM] shares were valued at $1.49 at the most recent close of the market.
Analyzing the ITRM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.78, Equity is -2.16 and Total Capital is -1.88. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of5.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3833 points at the first support level, and at 1.2767 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5833, and for the 2nd resistance point, it is at 1.6767.
Iterum Therapeutics Plc [ITRM] reported earnings per share of -$0.3 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.91/share, meaning a difference of $0.61 and a surprise factor of 67.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2022 were -$0.97 per share as compared to estimates of -$1.05 per share, a difference of $0.08 representing a surprise of 7.60%.
Ratios To Look Out For
For context, Iterum Therapeutics Plc’s Current Ratio is 2.35. In addition, the Quick Ratio stands at 2.35 and the Cash Ratio stands at 0.29.
Transactions by insiders
Recent insider trading involved Dunne Michael W., Director, that happened on Dec 22 ’23 when 25000.0 shares were purchased. Director, Dunne Michael W. completed a deal on Dec 18 ’23 to buy 10000.0 shares. Meanwhile, Director Dunne Michael W. bought 20000.0 shares on Nov 22 ’23.
